Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnibus appropriations signed

This article was originally published in The Tan Sheet

Executive Summary

President Bush signs H.J. Res. 2 Feb. 20, providing federal government $397.4 bil. for FY 2003. House and Senate agreed to conference report Feb. 13 (1"The Tan Sheet" Feb. 17, 2003, In Brief)...

You may also be interested in...



Omnibus spending bill

House, Senate agree to conference report on FY 2003 approps bill Feb. 13, providing $413.3 mil. for CFSAN, $426.7 mil. for CDER. Total FDA budget is $1.63 bil., including $222.9 mil. in PDUFA fees. Funding levels are similar to those in version passed by lower chamber (1"The Tan Sheet," Jan. 27, 2003, In Brief)...

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel